EMA issues qualification opinion for islet autoantibodies as enrichment biomarkers for T1D prevention trials

By | April 6, 2022
Critical Path Institute’s Type 1 Diabetes Consortium (T1DC) today announced that the European Medicines Agency has issued a positive qualification opinion for pancreatic islet autoantibodies as enrichment biomarkers for type 1 diabetes (T1D) prevention trials.